Cancer-targeting gene-viro-therapy is a promising cancer therapeutic strategy that strengthens the antitumor effect of oncolytic viruses by expressing an inserted foreign antitumor gene. To achieve liver cancer targeting and to improve the safety of the ZD55 vector (a widely-used E1B55KD gene-deleted oncolytic adenoviral vector (OV), we previously constructed), we designed a novel OV named Ad Á AFP Á D55 that selectively replicates in hepatocellular carcinoma (HCC) cells by replacing the E1A promoter with the liver-cancer specific a-Fetoprotein (AFP) promoter based on the ZD55 vector. We found that the oncolytic adenoviruses Ad Á AFP Á D55-IL-24 and Ad Á AFP Á D55-TRAIL express tumor-suppressor gene interleukin-24 (IL-24) and tumor necrosis factorrelated apoptosis-inducing ligand (TRAIL), respectively, significantly suppressed the HCC cell growth in vitro by inducing apoptosis by the caspase-8 and mitochondria-dependent caspase-9 signaling pathways. Furthermore, the combined treatment of Ad Á AFP Á D55-IL-24 and Ad Á AFP Á D55-TRAIL showed strong antitumor effects in vivo by significantly inhibiting the tumor growth in HCC HuH-7 cell xenograft mice, and markedly increasing animal survival rate. Therefore, this novel HCC cell-targeting OV carrying tumor-suppressor genes may provide a promising approach for liver cancer gene therapy.
Introduction
Cancer is one of the most malignant diseases we are facing. According to the World Health Statistics of WHO, nearly eight million people die of cancer each year worldwide. Many therapeutic strategies have been developed to treat cancer, including gene therapy and oncolytic adenoviral therapy. In 2001, we proposed a strategy that combined gene therapy and oncolytic viral therapy to treat cancer by inserting an antitumor gene into an oncolytic viral vector. We named this strategy as Cancertargeting gene-viro-therapy (CTGVT). 1 In principle, when the oncolytic virus vector (OV) replicates in cancer cells as a gene delivery vector, the carried foreign antitumor gene is also replicated. Without exception, our past 10 years of work on this strategy has demonstrated that CTGVT is a much more potent cancer therapeutic strategy than either gene therapy or oncolytic viral therapy.
Recently, we have developed several new CTGVT strategies, including the CTGVT-DG (Cancer-targeting dual gene-viro-therapy) strategy, which combines two tumor-suppressor genes that may have compensative or synergetic effects. We have shown that this new strategy can significantly suppress cancer cell growth and eradicate many xenograft tumors, such as cancer of liver, pancreas and lung. Furthermore, combined treatment with ZD55-IL-24 (an OV carrying foreign gene IL-24) and ZD55-TRAIL completely eradicated colorectal xenograft tumors. [2] [3] [4] [5] Interleukin-24 (IL-24), (also known as Mda-7, melanoma differentiation-associated gene-7) belongs to the interleukin 10 (IL-10)-related family. Overexpression of IL-24 can inhibit cancer cell growth and induce apoptosis in many cancer cell lines, including carcinomas of melanoma, breast, lung, cervix, gliomas, colon, pancreas and prostate. 6 Another antitumor gene, TRAIL (tumor necrosis factor-related apoptosis-inducing ligand), is a type II transmembrane protein related to TNF family factors and is considered to be a promising anticancer agent. 7 Much work has indicated that both the membrane-bound and the soluble extracellular domain of TRAIL can induce apoptosis in a broad type of tumor cells without affecting most normal cells. 8, 9 Moreover, we previously reported that the combination of two therapeutic genes mediated by replication-defective vectors can exert synergic or compensatory antitumor activities. 2, 4 Based on these studies, we decided to evaluate the effects of combined usage of IL-24 and TRAIL with a newly constructed dual-regulated OV Ad Á AFP Á D55, 10 whose replication was controlled by dual mechanisms (E1B-55KD deletion and E1A regulated by AFP promoter).
The viral vector previously used in CTGVT in our laboratory was the adenoviral vector ZD55 that was constructed by deleting the E1B-55KD gene of wild-type human adenovirus (Ad) 5.
11 This design was inspired by the first E1B-55KD gene-deleted oncolytic Ad ONYX-015. 12 We have demonstrated that the ZD55-gene system could be a potent antitumor strategy. 2, 11 Liver cancer is the most common malignant cancer in China, however, the OV ZD55 cannot specifically target liver cancer and even shows modest liver toxicity. 13 To overcome this obstacle, we developed an OV that specifically targeted hepatocellular carcinoma (HCC) cells and improved the safety by replacing the E1A promoter of the ZD55 vector with a liver-cancer specific a-Fetoprotein (AFP) promoter, which was reported to be preferentially expressed in over 70% of human liver cancer patients through transcriptional activation. 14, 15 We named this new OV as Ad Á AFP Á D55. In this work, we further inserted IL-24 and TRAIL genes individually into Ad Á AFP Á D55 to generate Ad Á AFP Á D55-IL-24 and Ad Á AFP Á D55-TRAIL, and then evaluated the combined antitumor effects of treatment with these two new oncolytic Ads in vitro and in vivo.
Materials and methods
Cell lines and culture conditions SW620 (human colorectal cancer cell line), A549 (human lung adenocarcinoma cell line), BEAS-2B (human normal bronchial epithelial cell line), Hep G2 (human HCC cell line) and MRC-5 (human embryonic fibroblast cell line) were obtained from ATCC (Rockville, MD). L-02 (human normal hepatocyte cell line), Hep 3B (human hepatoma cell line), HCCLM6 (human hepatoma cell line), HuH-6 (human hepatoma cell line) and HuH-7 (human hepatoma cell line) were obtained from the Cell Bank of Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China). HEK293 (human embryonic kidney cell line) was obtained from Microbix Biosystems Inc. (Toronto, Ontario, Canada). A549 and L-02 was grown in RPMI 1640 (GIBCO BRL, Grand Island, NY) supplemented with 4% fetal bovine serum (GIBCO BRL); SW620 was grown in Dulbecco's modified Eagle's medium (GIBCO BRL) supplemented with 4% fetal bovine serum. Other cell lines were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum.
Construction of the oncolytic adenoviral shuttle vectors
The construction of adenoviral shuttle plasmids for oncolytic adenovirus Ad Á AFP Á D55, Ad Á AFP Á D55-IL-24 and Ad Á AFP Á D55-TRAIL were performed, as we had previously described. 10 Generation, identification, production, purification and titration of recombinant adenovirus The recombinant adenoviruses (rec-Ads) were generated by respective homologous recombination between the shuttle plasmids and the packaging plasmid pBHGE3 in HEK293 cells. Detailed procedures on the generation, identification, production, purification and titration of the recombinant adenovirus can be found in our previous report. 10 Cytotoxicity assays Tumor cells and normal cells were seeded in 24-well plates, and were infected with adenoviruses at various multiplicity of infections (MOIs) 24 h later. At 96 h after infection, the medium was removed, and the cells were stained with 2% crystal violet in 20% methanol for 20 min. The plates were then washed with water and documented as photographs.
Cell viability assays
HuH-7 and Hep G2 cells were seeded in 96-well plates, 24 h later, they were infected with adenoviruses at an MOI of 1. At 24, 48, 72 and 96 h after infection, 20 ml of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (5 mg ml À1 ) was added to each well, and the plates were incubated at 37 1C for 4 h. The medium was then removed and 100 ml of 0.04 M HCl-isopropanol solution was added to each well. Absorbance was measured at 595 nm and 655 nm using a Microplate Reader (Thermo, Asheville, NC). For each assay, 10 replicate wells were counted.
DNA fragmentation assays
HuH-7 cells were seeded in 10-cm culture dishes and infected with various Ads. At 72 h post infection, DNA was extracted according to Herrmann's method 16 and analyzed using agarose gel electrophoresis.
Western blot assays
Cells were harvested and washed with phosphate-buffered saline (PBS), and then lysed in sodium dodecyl sulfate polyacrylamide gel electrophoresis sample buffer. Protein concentrations were determined using the Bio-Rad protein assay buffer (Bio-Rad, Hercules, CA). A total of 50 mg of protein was separated on 8-15% polyacrylamide gels and transferred to polyvinylidene fluoride membranes (Millipore, Billerica, MA). Western blots were carried out using standard procedures. Antibodies for actin, E1A, caspase-8, caspase-9, caspase-3, poly ADPribose polymerase, IL-24 and TRAIL were obtained from Santa Cruz Biotechnology (Santa Cruz, CA); antibody for E1B-55KD was obtained from Siemens Oncogene Science Inc. (Cambridge, MA); secondary antibodies were obtained from Santa Cruz Biotechnology.
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Flow cytometric analyses
For fluorescein isothiocyanate and propidium iodide double-staining FACS, an Annexin V-fluorescein isothiocyanate Kit (Bender MedSystems, Vienna, Austria) was used, and the cells were treated according to the manufacturer's instructions. The FACS assay was performed on a FACS Calibur flow cytometer (BD Biosciences, Franklin Lakes, NJ) immediately after staining. For JC-1 staining, cells were harvested and resuspended in 0.5 ml of medium. 0.5 ml of 5 mg ml À1 JC-1 fluorescent probe (Sigma, St Louis, MO) was added into the medium. Cells were incubated at 37 1C for 20 min and washed with PBS making them ready for FACS analyses.
Animal experiments
Animal experiments were performed according to the SIBS Guide for the Care and Use of Laboratory Animals. Female BALB/c nude mice (4-week-old) were purchased from the Shanghai Experimental Animal Center (Shanghai, China). To establish xenograft tumors, 5 Â 10 6 HuH-7 cells in 150 ml Dulbecco's modified Eagle's medium were subcutaneously injected into the right flank of each mouse. When tumors reached 100-150 mm 3 in volume, mice were divided randomly into five groups (8 mice per group). A total of 2 Â 10 9 plaque-forming units of adenoviruses per mouse or PBS (for control sample) were injected into the tumors for a total of four times every 48 h. Tumor volume (mm Immunohistochemistry and terminal deoxynucleotidyl transferase-mediated dUTPbiotin nick end labeling assays Tumor tissues were fixed in 4% formaldehyde, dehydrated with an ethanol gradient and embedded in paraffin. Tissue sections were dewaxed and rehydrated according to a standard protocol. The sections were washed with PBS, treated with 3% H 2 O 2 , and blocked with blocking solution. These steps were followed by overnight incubation with primary antibody at the proper dilution. Following the manufacturer's instructions, we used the mouse or goat ABC Staining System (Santa Cruz Biotechnology), and hematoxylin was used as a counterstain. Apoptotic cells in tumor tissue sections were assessed by TUNEL (terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling) staining with a TACS TdT Kit In Situ Apoptosis Detection Kit (R&D, Minneapolis, MN) according to the manufacturer's protocol. All sections were visualized with a Nikon Eclipse 80i microscope (Nikon, Tokyo, Japan).
Statistical analyses
All data were expressed as mean±s.d. and were analyzed using independent sample t-tests and one-way analyses of variance using SPSS Base 10.0. Results were considered statistically significant when Po0.05.
Results
Characterization of Ad Á AFP Á D55-IL-24 and Ad Á AFP Á D55-TRAIL We have previously confirmed the selective transcriptional activity of the AFP promoter in human AFPpositive HCC cells, 10 suggesting Ad Á AFP Á D55 could be an ideal HCC-targeting vector system. In this work, we inserted antitumor gene IL-24 or TRAIL into the OV Ad Á AFP Á D55 to enhance its curative effect (Figure 1a) . To exclude the possibility of Ad.WT contamination and study whether the E1A expression of Ad Á AFP Á D55 is under the control of the AFP promoter, the E1B-55KD and E1A expression levels were examined by western blot analysis. As shown in Figure 1b , the E1B-55KD protein was only detected in Ad.WT-infected cells, neither Ad Á AFP Á D55-IL-24 nor Ad Á AFP Á D55-TRAIL could induce E1B-55KD expression, suggesting no Ad.WT contamination in rec-Ads. Western blots also demonstrated that the E1A expression levels in Ad Á AFP Á D55-infected HCC cells were much higher than those in normal cells or non-HCC tumor cells (Figure 1b) . Because the E1A protein is critical to the replication of Ads, these results also provide direct evidence for the HCC-targeting replication ability of this OV. To verify whether the foreign IL-24 or TRAIL gene is expressed in vitro, we further infected HCC HuH-7 cells with Ad Á AFP Á D55-IL-24 and Ad Á AFP Á D55-TRAIL at an MOI of 10, and performed western blot studies 48 h later. As shown in Figure 1c , Ad Á AFP Á D55-IL-24 and Ad Á AFP Á D55-TRAIL infections could significantly induce IL-24 and TRAIL in HuH-7 cells, respectively; suggesting these OVs could efficiently express the carried foreign genes in vitro.
Ad Á AFP Á D55-IL-24/TRAIL specifically inhibits the proliferation of hepatoma cell lines. To evaluate the cytopathic effect induced by the rec-Ads, cell lines of liver cancer (HuH-7 and Hep G2), colorectal Figure 3c , about 18% of the cells infected with Ad Á AFP Á D55-IL-24 and about 13% with Ad Á AFP Á D55-TRAIL were stained with annexin V-positive, whereas infection with the combined Ads induced more potent apoptosis in HuH-7 cells, the number of annexin V-positive cells was about 29%.
Ad Á AFP Á D55-IL-24 and Ad Á AFP Á D55-TRAIL triggered caspase-mediated apoptosis signaling pathways To study the molecules involved in the process of apoptosis, we detected the apoptosis-associated proteins induced by various Ads in HuH-7 cells using immunoblotting. As shown in Figure 4a , the cleaved products of caspase-8, caspase-3 and poly ADP-ribose polymerase could be detected at 48 h after Ad Á AFP Á D55-IL-24 and Ad Á AFP Á D55-TRAIL infections. By the time of 72 h, the amount of cleavage products had further increased, which suggested that Ad Á AFP Á D55-IL-24 and Ad Á AFP Á D55-TRAIL induced caspases-mediated apoptosis in HuH-7 cells. Another notable result was that the combination of Ad Á AFP Á D55-IL-24 and Ad Á AFP Á D55-TRAIL treatment obviously induced the cleavage of caspase-9 (Figure 4a ), which implied that the combined treatment also activated the mitochondria-mediated signaling pathway.
We then used JC-1 staining to examine the mitochondrial transmembrane electrical potential (DCm) of HuH-7 cells at 48 h after infection. Ad Á AFP Á D55-TRAIL and Ad Á AFP Á D55-IL-24 induced a change in the DCm in HuH-7 cells (23.51 and 22.25%), whereas the combined treatment of two Ads induced an even more significantly altered DCm (39.58%) (Figure 4b ). All these results suggested that Ad Á AFP Á D55-IL-24 and Ad Á AFP Á D55-TRAIL induced apoptosis in HCC cells through modulating caspase-8 and the mitochondrial pathways.
Ad Á AFP Á D55-IL-24/TRAIL suppresses tumor growth in vivo The in vivo antitumor effects of Ad Á AFP Á D55-IL-24 and Ad Á AFP Á D55-TRAIL were evaluated in a HuH-7 tumor xenografts model. As shown in Figure 5a , at the end of 2 months of experiment duration, the average volume of the tumors of PBS-treated group reached approximately 2900 mm 3 ; in contrast, the growth of the combined Ads-treated tumors was obviously suppressed, with the average tumor volume at the same duration being only 300 mm 3 , representing a 90% suppression of Liver cancer-targeting gene-viro-therapy X Liu et al the xenograft tumor growth. In addition, Ad Á AFP Á D55-IL-24 or Ad Á AFP Á D55-TRAIL alone also showed tumor-suppression activity in vivo, although not as strong as the combined treatment (Figure 5a ).
The survival rate was also elevated in the mice treated with the combination of Ad Á AFP Á D55-IL-24 and Ad Á AFP Á D55-TRAIL. As shown in Figure 5b , 2 months after injection, all mice in the combination-treated group remained alive. In contrast, the survival rates of the PBStreated group, the Ad Á AFP Á D55-treated group and the Ad Á AFP Á D55-TRAIL-treated group were only 25%, 37.5% and 50%, respectively.
Ad Á AFP Á D55-IL-24/TRAIL induces apoptosis and necrosis in vivo To study the effect of Ads on the tumors in vivo, immunohistochemistry assays were carried out. After 7 days following the treatment, tumor sections were separated from tumor-bearing mice. As shown in Figure 6 , TRAIL and IL-24 were detected in tumor specimens, indicating that Ad Á AFP Á D55-TRAIL and Ad Á AFP Á D55-IL-24 successfully express the carried extraneous genes in vivo. H&E staining revealed large areas of necrotic tissue that matched the areas stained brown by the anti-hexon antibody after Ad Á AFP Á D55-IL-24 and Ad Á AFP Á D55-TRAIL treatments (Figure 6 ), suggesting that Ad-AFP Á D55-IL-24 and Ad Á AFP Á D55-TRAIL can effectively cause tumor necrosis in vivo. TUNEL analyses showed potent apoptosis both in the Ad Á AFP Á D55-IL-24-and Ad Á AFP Á D55-TRAIL-treated tumors, whereas no apoptosis was detected in the PBS-treated tumors. Therefore, we concluded that Ad Á AFP Á D55-IL-24 and Ad Á AFP Á D55-TRAIL exert antitumor activity in vivo by expressing IL-24 and TRAIL that subsequently induce apoptosis and necrosis in tumor cells.
Discussion
Many therapies have been used to treat cancer, including chemotherapy, radiotherapy, gene therapy and oncolytic viral therapy. All these therapies have limitations and for many types of cancer, complete curing cannot be achieved. The CTGVT provides a new promising approach, and our previous studies on CTGVT have shown satisfying antitumor effects. 11 The ZD55 vector we previously used in CTGVT is an adenovirus similar to the ONYX-015 in the deletion of E1B-55KD. However, ZD55 is an E1B-55KD-deleted mono-regulated vector without the ability to target a specific cancer. To achieve liver cancer targeting and improved safety, here we constructed a dual-regulated OV that specifically targets liver cancer and has lower cytotoxic effects in normal liver tissue. 10 Similar gene therapies specifically targeting liver cancer have been reported and some dual-regulated oncolytic HCC-targeting adenoviruses, such as YKL-1001 and AdAFPep/Rep, whose replication is also controlled by the AFP promoter, have been constructed. 17, 18 In the present study and also in our previous work, 10 we also found that the AFP promoter-controlled Ad Á AFP Á D55 can selectively replicate in liver cancer cells, suggesting that the constructed Ad Á AFP Á D55 can be used as a good liver-cancer targeting OV.
In CTGVT studies, a pro-apoptotic gene is usually applied as the antitumor gene, which is carried by the oncolytic virus vector. 2, 3 Although our previous results showed that the oncolytic virus armed with an antitumor gene could significantly enhance antitumor effects compared with the empty oncolytic virus, 2, 5 it remained unclear whether the harbored pro-apoptotic gene will impair the replication of viruses in tumor cells, as the induced apoptosis in infected cells may eliminate dissemination of viruses in the tumor mass. However, based on our long-term studies on CTGVT, we observed no (or very minor) effect on the replication of oncolytic viruses by harbored pro-apoptotic genes. 2, 5, 10 It will be of our future interests to investigate the relationship between apoptosis and oncolytic effects in tumor cells induced by Ads in detail. In this study, to strengthen the curative effect of the HCC-targeting oncolytic virus Ad Á AFP Á D55, we applied the concept of CTGVT-DG on liver cancer-targeting therapy by combining two rec-Ads that carry tumor suppressor genes TRAIL and IL-24 (Ad Á AFP Á D55-TRAIL and Ad Á AFP Á D55-IL-24) to treat liver cancer. This strategy showed satisfying antitumor effects both in vitro and in vivo. In vitro, we found that the Ads selectively inhibited the growth of the HCC cells through apoptosis, but did not affect normal cells. The molecules involved in the apoptosis mediated by the interaction between IL-24 and TRAIL were also studied. In vivo, although we have previously reported that hepatoma xenograft was not easily regressed by mono-gene-armed oncolytic Ad treatment due to the high malignancy of HCC cells, 19 combined treatment with Ad Á AFP Á D55-TRAIL and Ad Á AFP Á D55-IL-24 not only showed excellent oncolytic effect on HCC cells of xenograft mice (90% suppression of tumor growth), but also increased survival rate (Figure 5a ).
CTGVT-DG has been proven to be a promising treatment for various types of cancer, and we have reported different combinations of tumor suppressor genes that may have compensative or synergetic effects, including plasminogen k5/TRAIL, 5 short hairpin RNAs that target M-phase phosphoprotein 1 (shMPP1)/IL-24 20 and manganese superoxide dismutase (MnSOD)/ TRAIL in colorectal carcinoma, 4 and Smac/TRAIL in heptoma. 2 Here we also demonstrated strong antitumor effects of the combined treatment with rec-Ads carrying IL-24 and TRAIL, suggesting IL-24/TRAIL as a promising combination in liver cancer gene therapy. In fact, IL-24/TRAIL is not a novel combination of tumor suppressor genes, and we have previously reported its application in colorectal cancer gene therapy, 3 in which we found that ZD55-IL-24 could significantly upregulate TRAIL expression in colorectal tumor SW620 cells, and ZD55-IL-24 combined with ZD55-IL-TRAIL could completely eliminate colorectal tumor xenografts with an elevated survival rate. 3 Furthermore, it has also been demonstrated that both TRAIL and its receptor DR4 are upregulated in Ad-IL-24-treated lung cancer cells. 21 We also reported that both ZD55-IL-24 and its combination with ZD55-TRAIL could induce the expression of apoptotic death receptor DR4 in colorectal tumor SW620 cells. 3 We therefore believe that the upregulation of TRAIL and its receptor DR4 is a potential reason why the combination of these two Ads results in strong synergistic antitumor effects in liver cancer. However, more evidence is still needed to discover the exact underlying mechanism.
In conclusion, our present work on the liver cancertargeting Dual-gene-viro-therapy strategy provides a promising approach for hepatoma therapy. It has been shown that deleting a small viral protein E4-orf3 can bring higher safety to the oncolytic adenovirus; 22 and liver cancer suppressor gene, such as HCCS1 or SOCS3, Liver cancer-targeting gene-viro-therapy X Liu et al have been shown to specifically inhibit liver tumorigenesis. 19, 23 It will be our future interest to improve the presently used HCC-targeting OV Ad Á AFP Á D55 and select more appropriate antitumor genes using these strategies. Figure 6 Histopathologic, immunohistochemical and terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling (TUNEL) analyses of tumor sections. Tumor sections were separated and fixed in 4% paraformaldehyde, embedded in paraffin, and cut in 4-mm sections. Then, immunochemical analyses for hexon, interleukin-24 (IL-24) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), TUNEL and hematoxylin and eosin (H&E) staining assays of tumor sections in different groups were performed. Scale bar ¼ 20 mm.
